News to know
Whether it’s health or education policy changes or new research about neurodivergence, we help you make sense of the headlines — so you can make informed decisions for you and your family.
Trump administration splits special education oversight between HHS and DOJ
Featured stories
FDA approves Simtriyo (centanafadine), a ‘first of its kind’ ADHD medication
The Food and Drug Administration (FDA) just approved Simtriyo (centanafadine), a new norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) and central nervous system stimulant. The medication treats ADHD in adults, teens, and children ages 6 and up weighing at least 44 pounds. Most stimulant and non-stimulant ADHD medications raise the levels of two different brain chemicals related to A
How the Trump administration is changing federal oversight of special education
Updated on July 30 with the latest news from Congress. On June 16, 2026, the U.S. Department of Education announced that it’s splitting oversight of special education between the U.S. Department of Health and Human Services (HHS) and the Department of Justice (DOJ). Special education exists so that students with disabilities can participate, learn, and make progress in school alongside their pee
Zero Reject: The Uncertain Future of Special Education
Reduction in force | 1
When the office protecting disabled students’ civil rights was gutted, one attorney watched a lifeline for families disappear overnight.
25,000 complaints, and 7 minutes | 2
Her son could only read four words at age 7. Her federal special ed complaint is one of 25,000 stuck with no answer. Zero Reject investigates.
ADHD in the news
Education news
Your gift could be someone’s next step.
A parent searching for answers at their lowest moment found what they needed here — for free — because someone gave first. Your gift makes it possible for the next one.
Donate to Understood now
100% of your contribution funds our research and expert-vetted resources.
